ORAL ANTICOAGULANTS IN PATIENTS WITH DIFFERENT FORMS OF PULMONARY ARTERIAL HYPERTENSION, ASPECTS OF THE PROBLEM
https://doi.org/10.38109/2225-1685-2017-4-122-132
Abstract
The use of direct oral anticoagulants in patients with pulmonary arterial hypertension (PAH) has remained a controversial issue for a decade. Despite the lack of solid evidence from well-controlled prospective trials, anticoagulation has been recommended for patients with idiopathic pulmonary arterial hypertension (IPAH), but it is unclear whether this recommendation should be extrapolated to patients with other forms of PAH. In this review, we discuss the current opportunities and problematic aspects of oral anticoagulation therapy in different forms of PAH, the influence on disease course and prognosis..
About the Authors
S. Ye. Gratsianskaya
National Medical Research Centre of cardiology of Ministry of Health
Russian Federation
Russian Federation
Medical resident of the department of pulmonary hypertension and heart disease
8-495-414-68-42
T. V. Martynyuk
National Medical Research Centre of cardiology of Ministry of Health
Russian Federation
Russian Federation
MD, leading researcher, head of the department of pulmonary hypertension and heart disease
121552, Moscow, 3rd Street Cherepkovskaya, Building 15a,
8-495-414-64-50
S. N. Nakonechnikov
National Medical Research Center for Cardiology of the Ministry of Health
Russian Federation
Russian Federation
Deputy director general
121552, Moscow, 3rd Street Cherepkovskaya, Building 15a
8-495-414-61-18
I. Ye. Chazova
National Medical Research Centre of cardiology of Ministry of Health
Russian Federation
Russian Federation
Academician of Russian Academy of Sciences, Professor, MD, Director, Head of Department
121552, Moscow, 3rd Street Cherepkovskaya, Building 15a
8-495-415-52-05
References
1. Saeed W., Tiawari N., Sardar M.R. et al. Effect of Warfarin on Long Term Pulmonary Arterial Hypertension (PAH) Mortality: Change of facts? // Circulation. – 2011. – Vol. 124. – P. A16034.
2. Galie` N., Humbert M., Vachiery J.-L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension // Eur Heart J. – 2016. – Vol. 37. – P. 67 – 124.
3. Caldeira D., Loureiro M.J., Costa J. et al. Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis // Can J Cardiol. – 2014. – Vol. 30. – P. 879–87.
4. Chazova I.Ye., Martynyuk T.V., Nakonechnikov S.N. Results of the European Congress of Cardiology 2015: a new version of the recommendations for the diagnosis and treatment of pulmonary hypertension // Eurasian Cardiology Journal. - 2015. - Vol. 4. - P. 3-10 [in Russian].
5. Geyer M, Müller-Ladner U. The pathogenesis of systemic sclerosis revisited // Clin Rev Allergy Immunol. – 2011. – Vol. 40. – P. 92–103.
6. Olsson K.M., Delcroix M., Ghofrani H.A. et al. Anticoagulation and Survival in Pulmonary Arterial Hypertension Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) // Circulation. – 2014. – Vol. 129. – P. 57-65.
7. Nikpour M., Baron M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies // Curr Opin Rheumatol. – 2014. – Vol. 26. – P. 131–7.
8. Johnson S.R., Granton J.T., Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension // Chest. – 2006. Vol. 130. – P. 545–552.
9. Komócsi A., Vorobcsuk A., Faludi R. et al. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies // Rheumatology (Oxford). – 2012. – Vol. 51. – P.1027–36.
10. Opitz C.F., Kirch W., Mueller E.A. et al. Bleeding events in pulmonary arterial hypertension // Eur J Clin Invest. – 2009. – Vol. 39. – Suppl 2. – P. 68–73.
11. Elhai M., Meune C., Avouac J. et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies // Rheumatology (Oxford). – 2012. – Vol. 51. – P. 1017–26.
12. Sandoval J., Santos L.E., Córdova J. et al. Does anticoagulation in Eisenmenger syndrome impact long-term survival? // Congenit Heart Dis. – 2012. – Vol. 7. – P. 268-276.
13. Tyndall A.J., Bannert B., Vonk M., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database // Ann Rheum Dis. – 2010. – Vol. 69. –P. 1809–15.
14. Wagenvoort C.A., Wagenvoort N. Primary pulmonary hypertension: A pathologic study of the lung vessels in 156 clinically diagnosed cases // Circulation. – 1970. – Vol. 42. – P. 1163-1184.
15. Berger G., Azzam Z.S., Hoffman R., et al. Coagulation and anticoagulation in pulmonary arterial hypertension // Isr Med Assoc J. – 2009. – Vol.11. – P. 376–9.
16. Wagenvoort C.A. Vasoconstrictive primary pulmonary hypertension and pulmonary veno-occlusive disease // Cardiovasc Clin. – 1972. – Vol. 4. – P. 97–113.
17. Johnson S.R., Granton J.T., Tomlinson G.A. et al. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease // J Rheumatol. – 2012. – Vol. 39. –P. 276–85.
18. Wagenvoort C.A., Wagenvoort N. Pathology of the Eisenmenger syndrome and primary pulmonary hypertension // Adv Cardiol. – 1974. – Vol. 11. – P.123–130.
19. Nikpour M., Stevens W., Proudman S.M., et al. Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated? // Intern Med J. – 2013. – Vol. 43. – P. 599–603.
20. Huber K., Beckmann R., Frank H. et al. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension // Am J Respir Crit Care Med. – 1994. – Vol. 150. – P. 929-933.
21. Preston I.R., Roberts K.E., Miller D.P., et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and LongTerm PAH Disease Management (REVEAL) // Circulation. – 2015. – Vol. 132. – P. 2403–11.
22. Hoeper M.M., Sosada M., Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension // Eur Respir J. – 1998. – Vol.12. – P. 1446–1449.
23. Calderone A., Stevens W., Prior D., et al. Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol // BMJ Open. – 2016. – Vol. 6. - e011028.
24. Bonderman D., Turecek P.L., Jakowitsch J. et al. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension // Thromb Haemost. – 2003. – Vol. 90. – P. 372–376.
25. Fuster V., Steele P.M., Edwards W.D. et al. Primary pulmonary hypertension: natural history and the importance of thrombosis // Circulation. - 1984. – Vol. 70. – P. 580–587.
26. Kaemmerer H., Gorenflo M., Hoeper M. et al. Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation // Dtsch Med Wochenschr. – 2013. – Vol. 138. – P. 1247-52.
27. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension // N Engl J Med. - 1992. – Vol. 327. – P. 76–81.
28. Delbeck M., Nickel K.F., Perzborn E. et al. A role for coagulation factor Xa in experimental pulmonary arterial hypertension // Cardiovascular Research. – 2011. – Vol. 92. – P. 159–168.
29. Johnson S.R., Mehta S., Granton J.T. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review // Eur Respir J. – 2006. – Vol. 28. – P. 999–1004.
30. Kim N.H., Delcroix M., Jenkins D.P. et al. Chronic Thromboembolic Pulmonary Hypertension // J Am Coll Cardiol. – 2013. – Vol. 62(Suppl). – P. 92–99.
31. Galiè N., Manes A., Negro L. et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension // Eur Heart J. – 2009. – Vol. 30. – P. 394–403.
32. Martyniuk T.V., Dadacheva Z.Kh., Chazova I.Ye. Possibilities of drug treatment of chronic thromboembolic pulmonary hypertension // Atherothrombosis. – 2015. – No. 1. – P. 87-98 [in Russian].
33. Humbert M., Sitbon O., Chaouat A. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era // Circulation. – 2010. – Vol. 122. – P. 156–163.
34. Dyakov I. New oral anticoagulants – a place on the domestic pharmaceutical market // Remedium. – 2015 [in Russian].
35. Frost A.E., Badesch D.B., Barst R.J. et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries // Chest. – 2011. – Vol. 139. – P. 128–137.
36. Panchenko E.P. New oral anticoagulants in patients with non-valvular atrial fibrillation and chronic kidney disease // Atherothrombosis. – 2015. – No. 2. – P. 51-57 [in Russian].
37. Badesch D.B., Raskob G.E., Elliott C.G. et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry // Chest. – 2010. – Vol. 137. – P. 376–387.
38. Hoeper M.M., Huscher D., Ghofrani H.A. et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry // Int J Cardiol. – 2013. – Vol. 168. – P. 871–880.
39. Ling Y., Johnson M.K., Kiely D.G. et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland // Am J Respir Crit Care Med. – 2012. – Vol. 186. – P. 790–796.
40. Henkens I.R., Hazenoot T., Boonstra A. et al. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension // Eur Respir J. – 2013. – Vol. 41. – P. 872–878.
41. Ngian G.S., Stevens W., Prior D., et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study // Arthritis Res Ther. – 2012. –
42. Vol. 14. – P. 213.
43. Storstein O., Efskind L., Müller C. et al. Primary pulmonary hypertension with emphasis on its etiology and treatment // Acta Med Scand. – 1966. – Vol. 179. – P. 197-212.
44. Ogata M., Ohe M., Shirato K. et al. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension // Jpn Circ J. – 1993. – Vol. 57. – P. 63-9.
45. Frank H., Mlczoch J., Huber K. et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension // Chest. – 1997. – Vol. 112. – P. 714-21.
46. Kawut S.M., Horn E.M., Berekashvili K.K. et al. New predictors of outcome in idiopathic pulmonary arterial hypertension // Am J Cardiol. – 2005. – Vol. 95. – P.199-203.
47. Saeed W., Tiawari N., Sardar M.R. et al. Effect of Warfarin on Long Term Pulmonary Arterial Hypertension (PAH) Mortality: Change of facts? // Circulation. – 2011. – Vol. 124. – P. A16034.
48. Caldeira D., Loureiro M.J., Costa J. et al. Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis // Can J Cardiol. – 2014. – Vol. 30. – P. 879–87.
49. Geyer M, Müller-Ladner U. The pathogenesis of systemic sclerosis revisited // Clin Rev Allergy Immunol. – 2011. – Vol. 40. – P. 92–103.
50. Nikpour M., Baron M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies // Curr Opin Rheumatol. – 2014. – Vol. 26. – P. 131–7.
51. Komócsi A., Vorobcsuk A., Faludi R. et al. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies // Rheumatology (Oxford). – 2012. – Vol. 51. – P.1027–36.
52. Elhai M., Meune C., Avouac J. et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies // Rheumatology (Oxford). – 2012. – Vol. 51. – P. 1017–26.
53. Tyndall A.J., Bannert B., Vonk M., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database // Ann Rheum Dis. – 2010. – Vol. 69. –P. 1809–15.
54. Berger G., Azzam Z.S., Hoffman R., et al. Coagulation and anticoagulation in pulmonary arterial hypertension // Isr Med Assoc J. – 2009. – Vol.11. – P. 376–9.
55. Johnson S.R., Granton J.T., Tomlinson G.A. et al. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease // J Rheumatol. – 2012. – Vol. 39. –P. 276–85.
56. Nikpour M., Stevens W., Proudman S.M., et al. Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated? // Intern Med J. – 2013. – Vol. 43. – P. 599–603.
57. Preston I.R., Roberts K.E., Miller D.P., et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and LongTerm PAH Disease Management (REVEAL) // Circulation. – 2015. – Vol. 132. – P. 2403–11.
58. Calderone A., Stevens W., Prior D., et al. Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol // BMJ Open. – 2016. – Vol. 6. - e011028.
59. Kaemmerer H., Gorenflo M., Hoeper M. et al. Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation // Dtsch Med Wochenschr. – 2013. – Vol. 138. – P. 1247-52.
60. Delbeck M., Nickel K.F., Perzborn E. et al. A role for coagulation factor Xa in experimental pulmonary arterial hypertension // Cardiovascular Research. – 2011. – Vol. 92. – P. 159–168.
61. Kim N.H., Delcroix M., Jenkins D.P. et al. Chronic Thromboembolic Pulmonary Hypertension // J Am Coll Cardiol. – 2013. – Vol. 62(Suppl). – P. 92–99.
62. Martyniuk T.V., Dadacheva Z.Kh., Chazova I.Ye. Possibilities of drug treatment of chronic thromboembolic pulmonary hypertension // Atherothrombosis. – 2015. – No. 1. – P. 87-98 [in Russian].
63. Dyakov I. New oral anticoagulants – a place on the domestic pharmaceutical market // Remedium. – 2015 [in Russian].
64. Panchenko E.P. New oral anticoagulants in patients with non-valvular atrial fibrillation and chronic kidney disease // Atherothrombosis. – 2015. – No. 2. – P. 51-57 [in Russian].
Review
For citations:
Gratsianskaya S.Ye., Martynyuk T.V., Nakonechnikov S.N., Chazova I.Ye. ORAL ANTICOAGULANTS IN PATIENTS WITH DIFFERENT FORMS OF PULMONARY ARTERIAL HYPERTENSION, ASPECTS OF THE PROBLEM. Eurasian heart journal. 2017;(4):122-132. https://doi.org/10.38109/2225-1685-2017-4-122-132
Views:
451
Email this article 
